<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>BUSINESS DIGEST</title>
    <meta content="17DIGE" name="slug"/>
    <meta content="17" name="publication_day_of_month"/>
    <meta content="10" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Tuesday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="1" name="print_page_number"/>
    <meta content="C" name="print_section"/>
    <meta content="1" name="print_column"/>
    <meta content="Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1239513"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">NO INDEX TERMS FROM NYTIMES</classifier>
        <classifier class="online_producer" type="types_of_material">Summary</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20001017T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9D0DE4D61F3FF934A25753C1A9669C8B63" item-length="1036" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>BUSINESS DIGEST</hl1>
      </hedline>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>Biotechnology Companies In a $900 Million Merger  Corixa agreed to buy Coulter Pharmaceutical, gaining access to a potentially promising cancer drug and a sales force. The acquisition, for stock worth about $900 million when the deal was announced, is one of the largest ever between two biotechnology companies.</p>
        <p>Corixa is developing vaccines and other drugs that seek to harness the body's immune system. Coulter works in the closely related area of monoclonal antibodies, which are engineered versions of proteins the immune system uses to fend off bacteria or viruses. Shares of Corixa fell $4.50, to $39.69. Coulter rose $3.94, to $34.88. [Page C10.]</p>
      </block>
      <block class="full_text">
        <p>Biotechnology Companies In a $900 Million Merger  Corixa agreed to buy Coulter Pharmaceutical, gaining access to a potentially promising cancer drug and a sales force. The acquisition, for stock worth about $900 million when the deal was announced, is one of the largest ever between two biotechnology companies.</p>
        <p>Corixa is developing vaccines and other drugs that seek to harness the body's immune system. Coulter works in the closely related area of monoclonal antibodies, which are engineered versions of proteins the immune system uses to fend off bacteria or viruses. Shares of Corixa fell $4.50, to $39.69. Coulter rose $3.94, to $34.88. [Page C10.]</p>
        <p>Continental Air Profit Rises 32%  Continental Airlines said that its third-quarter profit rose 32 percent, surpassing expectations, on increased demand for business travel. But some analysts warned that profits for the industry would not be as strong as in the last quarter because of higher oil prices. [C2.]</p>
        <p>Nasdaq Slips, but Dow Ends Higher  The main stock market gauges were narrowly mixed as worries about third-quarter earnings continued to trouble investors. The Nasdaq composite index fell 26.49 points, or 0.8 percent, to 3,290.28. But the Dow Jones industrial average rose 46.62 points, or 0.5 percent, to 10,238.80, and the Standard &amp; Poor's 500-stock index edged up 0.45 point, to 1,374.62. [C17.]</p>
        <p>Suit Refiled Over Fraudulent Goods  Seven users of eBay refiled a lawsuit against the company, accusing eBay of neglecting to protect consumers from sales of forged sports memorabilia in its auctions. EBay says that it merely operates a conduit for sales. [C10.]</p>
        <p>Euro Drops Near Its Record Low  Europe's unified currency, the euro, fell to a level just above its low against the dollar after Europe's chief central banker made comments that appeared to play down chances of further market intervention. In New York, the euro settled at 85.05 cents, down from 85.44 cents on Friday. The euro reached a low of 84.72 cents in New York on Sept. 20. [C17.]</p>
        <p>Geologist for Bre-X Goes on Trial  Nearly three years after Bre-X Minerals collapsed in one of the biggest gold-discovery frauds of all time, its chief geologist went on trial in the only criminal prosecution arising from a scandal that wiped out holdings of investors in Canada and the United States. [C2.]</p>
        <p>Boo.com Prepares for a Rebirth  Boo.com, one of online fashion's first victims, is preparing for its reappearance on Oct. 30. Beginning this week, the new Boo is introducing itself with billboard posters and print ads in London and New York. [C8.]</p>
        <p>Business Inventories Rise 0.7%  Inventories at businesses rose 0.7 percent in August after a 0.4 percent increase in July, the government said in a report consistent with a picture of slowing economic growth. [C2.]</p>
        <p>Lieberman's Interest in Accounting  Six years ago, Senator Joseph I. Lieberman was instrumental in derailing stricter accounting rules on stock options. And earlier this year, Senator Lieberman, now the Democratic vice presidential candidate, joined 12 other senators in pushing for a delay of new rules on acquisitions that could hurt the bottom line of businesses. Market Place. [C16.]</p>
        <p>Indonesia Seeks to Deflect Criticism  The Indonesian government, which presides over the weakest of Southeast Asia's economies, is rebuffing criticism from international donors even as it approaches them for $4.8 billion. [World Business, Section W.]</p>
      </block>
    </body.content>
  </body>
</nitf>
